| Autor: |
Maria Suprun, Anais Levescot, Marla Dubinsky, Lauren A. Peters, Judy H. Cho, Carrie Brodmerkel, Bruce E. Sands, Saurabh Mehandru, Lishomwa C. Ndhlovu, Joshua R. Friedman, Ruiqi Huang, Eric E. Schadt, Bojan Losic, Carmen Argmann, Antonio Di’Narzo, Ke Hao, Ryan C. Ungaro, Divya Jha, Gabrielle Wei, Jean-Frederic Colombel, Mark Curran, Sander M. Houten, Sascha Cording, Alexandra E. Livanos, Aleksandar Stojmirović, Roman Kosoy, Huaibin M. Ko, Minami Tokuyama, Michael J. Corley, Wenhui Wang, Andrew Kasarskis, Jun Zhu, Gustavo Martinez-Delgado, Jacqueline Perrigoue, Mayte Suárez-Fariñas, Nadine Cerf-Bensusan, Haritz Irizar, Noam Harpaz |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Gastroenterology |
| DOI: |
10.1101/2020.05.21.109124 |
| Popis: |
Background and Aims The presence of gastrointestinal symptoms and high levels of viral RNA in the stool suggest active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication within enterocytes. Methods Here, in multiple, large cohorts of patients with inflammatory bowel disease (IBD), we have studied the intersections between Coronavirus Disease 2019 (COVID-19), intestinal inflammation, and IBD treatment. Results A striking expression of ACE2 on the small bowel enterocyte brush border supports intestinal infectivity by SARS-CoV-2. Commonly used IBD medications, both biologic and nonbiologic, do not significantly impact ACE2 and TMPRSS2 receptor expression in the uninflamed intestines. In addition, we have defined molecular responses to COVID-19 infection that are also enriched in IBD, pointing to shared molecular networks between COVID-19 and IBD. Conclusions These data generate a novel appreciation of the confluence of COVID-19– and IBD-associated inflammation and provide mechanistic insights supporting further investigation of specific IBD drugs in the treatment of COVID-19. Preprint doi: https://doi.org/10.1101/2020.05.21.109124 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
